SCHEMBL2980975

SCHEMBL2980975

CC1=NC(c2ccccc2)(c2ccccc2)C(=O)N1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 10/20 0.61
BACE2 Q9Y5Z0 6/20 0.61
CYP2C9 P11712 2/20 0.61
BLM P54132 2/20 0.61
PMP22 Q01453 2/20 0.61
KMT2A Q03164 2/20 0.61
LMNA P02545 2/20 0.61
GLA P06280 1/20 0.61
THRB P10828 1/20 0.61
APP P05067 2/20 0.43
REN P00797 1/20 0.43
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
ALDH1A1 P00352 2/20 0.38
CACNA1F O60840 1/20 0.38
MAPT P10636 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
SCN1A P35498 1/20 0.38
SCN4A P35499 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6827374 0.81 BACE1 (0.41) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL6589904 0.77 BACE1 (0.53) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL4239036 0.76 BACE1 (1.00) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL6591928 0.76 BACE1 (0.61) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL6593802 0.73 BACE1 (0.49) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL2575231 0.73 KDM4E (0.35) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL2975818 0.72 MMP2 (0.41) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL8175293 0.72 BACE1 (0.51) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL8162305 0.70 BACE1 (0.49) BACE1BACE2CYP2C9BLMPMP22
SCHEMBL8162233 0.70 BACE1 (0.49) BACE1BACE2CYP2C9BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786155-B2 Organic compounds NOVARTIS AG (CH) 2010-08-31 US disclosed
EP-2212295-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050201-A2 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099244-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099244-A1 ORGANIC COMPOUNDS SLCO4C1, SLC10A6, SLCO1B1 BACE1 2113/4885BACE2 3063/4885CYP2C9 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.